BUN/Cr-based Hydration Therapy to Improve Outcomes for Dehydrated Patients With Acute Ischemic Stroke. (HYDO)
Primary Purpose
Stroke, Dehydration
Status
Completed
Phase
Phase 3
Locations
Taiwan
Study Type
Interventional
Intervention
normal saline
Sponsored by
About this trial
This is an interventional treatment trial for Stroke focused on measuring Stroke, Dehydration, Fluid Therapy
Eligibility Criteria
Inclusion Criteria:
- Acute ischemic stroke diagnosed by the clinical presentations and brain imaging is confirmed by a stroke care specialist.
- has a measurable neurologic deficit according to the National Institutes of Health Stroke Scale (NIHSS)
- the time between the onset of neurological symptoms and starting therapy are less than 12 hours
- admission BUN/Cr≧15
Exclusion Criteria:
- no informed consent obtained
- initial NIHSS >15
- prepared for or received fibrinolytic therapy
- prepared for or received surgical intervention with 14 days
- congestive heart failure according to past history or Framingham criteria
- history of liver cirrhosis or severe liver dysfunction (alanine aminotransferase or aspartate aminotransferase > x 3 upper normal limit)
- admission blood Cr >2 mg/dl
- initial systolic blood pressure <90 mmHg
- fever with core temperature >=38°C
- indication of diuretics for fluid overload
- any conditions needed more aggressive hydration or blood transfusion
- cancer under treatment
- life expectancy or any reasons for follow-up < 3 months
Sites / Locations
- Chang Gung Memorial Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
No Intervention
Arm Label
normal saline, bolus
normal saline, control
Arm Description
Patients of study group will receive intravenous normal saline 20cc per kilogram of body weight, one third of which will be given as a bolus followed by delivery of the remaining two third as a constant infusion over a period of 8 hours.
Patients of control group will receive intravenous normal saline 60 cc per hour.
Outcomes
Primary Outcome Measures
rate of stroke-in-evolution
Stroke-in-evolution is defined as a deterioration from base line in the score on the NIHSS by 4 or more points.
Secondary Outcome Measures
rate of favorable outcome
Scores of >=60 on the Barthel index, <=2 on the modified Rankin scale are considered to indicate a favorable outcome.
Full Information
NCT ID
NCT02099383
First Posted
March 26, 2014
Last Updated
September 5, 2021
Sponsor
Chang Gung Memorial Hospital
1. Study Identification
Unique Protocol Identification Number
NCT02099383
Brief Title
BUN/Cr-based Hydration Therapy to Improve Outcomes for Dehydrated Patients With Acute Ischemic Stroke.
Acronym
HYDO
Official Title
A Phase III Trial of BUN/Cr-based Hydration Therapy to Reduce Stroke-in-evolution and Improve Short-term Functional Outcomes for Dehydrated Patients With Acute Ischemic Stroke
Study Type
Interventional
2. Study Status
Record Verification Date
November 2018
Overall Recruitment Status
Completed
Study Start Date
April 2014 (undefined)
Primary Completion Date
July 2020 (Actual)
Study Completion Date
July 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Chang Gung Memorial Hospital
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The investigators' preliminary findings suggest that providing patients with acute ischemic stroke hydration therapy on the basis of their presenting BUN/Cr ratio may help reduce the occurrence of stroke-in-evolution(SIE) and therefore improve prognosis.
The trial will be carried out in two parts. Part 1 assesses the rate of stroke-in-evolution 72 hours after the onset of stroke as a measure of the activity of BUN/Cr ratio based hydration therapy. Part 2, The investigators use two outcome measures, including Barthel index, and modified Rankin scale for neurological evaluation to assess whether BUN/Cr ratio based hydration therapy results in sustained clinical benefit at three months.
Detailed Description
The investigators have recently reported a novel finding that the blood urea nitrogen (BUN)/creatinine (Cr) ratio, a marker of hydration status, was an independent predictor of SIE among patients who had suffered acute ischemic stroke. The investigators found that patients who had a BUN/Cr ratio ≥ 15 were 3.4-fold more likely to experience SIE than patients who had a BUN/Cr ratio < 15. The ratio of SIE was 13.9% in all patients, with 20% in patients who had a BUN/Cr ratio ≥ 15 and 8.3% in patients who had a BUN/Cr ratio < 15. Among the patients presenting with acute ischemic stroke, 37% of them had a BUN/Cr ratio ≥ 15.
The investigators' recent pilot study was designed to determine if providing hydration therapy, specifically intravenous saline infusion, to patients with a blood urea nitrogen/creatinine ratio (BUN/Cr) ≥15 reduces the occurrence of SIE after acute ischemic stroke. Patients in the hydration group received a significantly larger (all P < 0.001) median volume of infused saline than patients in the control group. And this allowed 82% of the patients to maintain their BUN/Cr ratio <15 in first 8 hours. The proportion of patients who experienced SIE was significantly lower in the hydration group compared with the control group.
Dehydration, as indicated by an increased BUN/Cr ratio, is known to be relatively common among patients who have experienced stroke. According to the result of our pilot study, a hydration strategy with intravenous 20 cc per kilogram of body weight normal saline in first 8 hours was safe and effective to prevent dehydration related early neurological deterioration.
In this study, the investigators conduct a randomized double-blind control trial to test the hypothesis that whether BUN/Cr ratio based hydration therapy has clinical activity.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stroke, Dehydration
Keywords
Stroke, Dehydration, Fluid Therapy
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
244 (Actual)
8. Arms, Groups, and Interventions
Arm Title
normal saline, bolus
Arm Type
Active Comparator
Arm Description
Patients of study group will receive intravenous normal saline 20cc per kilogram of body weight, one third of which will be given as a bolus followed by delivery of the remaining two third as a constant infusion over a period of 8 hours.
Arm Title
normal saline, control
Arm Type
No Intervention
Arm Description
Patients of control group will receive intravenous normal saline 60 cc per hour.
Intervention Type
Other
Intervention Name(s)
normal saline
Intervention Description
intravenous normal saline 20cc per kilogram of body weight over a period of 8 hours
Primary Outcome Measure Information:
Title
rate of stroke-in-evolution
Description
Stroke-in-evolution is defined as a deterioration from base line in the score on the NIHSS by 4 or more points.
Time Frame
72 hours
Secondary Outcome Measure Information:
Title
rate of favorable outcome
Description
Scores of >=60 on the Barthel index, <=2 on the modified Rankin scale are considered to indicate a favorable outcome.
Time Frame
three months
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Acute ischemic stroke diagnosed by the clinical presentations and brain imaging is confirmed by a stroke care specialist.
has a measurable neurologic deficit according to the National Institutes of Health Stroke Scale (NIHSS)
the time between the onset of neurological symptoms and starting therapy are less than 12 hours
admission BUN/Cr≧15
Exclusion Criteria:
no informed consent obtained
initial NIHSS >15
prepared for or received fibrinolytic therapy
prepared for or received surgical intervention with 14 days
congestive heart failure according to past history or Framingham criteria
history of liver cirrhosis or severe liver dysfunction (alanine aminotransferase or aspartate aminotransferase > x 3 upper normal limit)
admission blood Cr >2 mg/dl
initial systolic blood pressure <90 mmHg
fever with core temperature >=38°C
indication of diuretics for fluid overload
any conditions needed more aggressive hydration or blood transfusion
cancer under treatment
life expectancy or any reasons for follow-up < 3 months
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Leng C Lin, MD
Organizational Affiliation
Department of Emergency Medicine, Chang Gung Memorial Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Chang Gung Memorial Hospital
City
Chiayi
ZIP/Postal Code
613
Country
Taiwan
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Citations:
PubMed Identifier
20825831
Citation
Lin LC, Yang JT, Weng HH, Hsiao CT, Lai SL, Fann WC. Predictors of early clinical deterioration after acute ischemic stroke. Am J Emerg Med. 2011 Jul;29(6):577-81. doi: 10.1016/j.ajem.2009.12.019. Epub 2010 Apr 2.
Results Reference
background
Learn more about this trial
BUN/Cr-based Hydration Therapy to Improve Outcomes for Dehydrated Patients With Acute Ischemic Stroke.
We'll reach out to this number within 24 hrs